Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 19, 2024 (3 years ago)

Omeza Skin Protectant

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Omeza Skin Protectant, Skin Protectant Gel 10*2mL Vials

Recalling firm
Omeza LLC
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0289-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Omeza LLC

All 2024 recalls

Other cgmp deviation recalls from 2024

All cgmp deviation recalls
Class II · Moderate risk

Henry Schein

CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Terminated cGMP deviation Keystone Industries D-0148-2025